Together, they are used to protect against the novel coronavirus pneumoniamRNAIn international disputes over patents, Modena (Moderna) Again, I failed. In the first civil court ruling on the dispute, The District Court in The Hague has struck down one of Modena's patents.

Modena sued Pfizer of the United States (Pfizer) And German drug makersBioNTechVaccine forComirnatyViolate two of themmRNAVaccine patent. plaintiff2022Proceedings were initiated against the accused in several countries at the end of the year, Demand its competitors based on2022years3month8Compensation is provided for all sales carried out after the date. Number asEP3590949B1andEP3718565B1The patents involved are related to "containn1-Ribonucleic acid of methylpseudouracil and its use" and "Respiratory virus vaccine" . however, Although both of these patents are related tomRNAvaccine-related, But they have different indications. EP3590949B1No. 1 Patent covers "embellishedmRNA" claim. EP3718565B1Patent covered "βcoronavirusmRNA-LNPvaccine" , It is an improved substance used to prevent infection with the novel coronavirus and other respiratory diseases.

Successful counterclaim

The defendant filed an invalid counterclaim. now, The Hague District Court declared NoEP3590949B1The patent is invalid in the Netherlands for lack of novelty. therewith, A spokesman for Modena said: "We are disappointed by the court's decision, The decision will be appealed. We still believe, In this case, Modena will win in the end. "

Just a few weeks ago, The oppositions Division of the European Patent Office in an oppositions case quashed the NoEP3718565B1Patent No. meanwhile, Modena has also appealed the decision. According to theBioNTechAnd Pfizer representatives said, The corresponding infringement proceedings in the Netherlands are currently suspended, The parties are awaiting the decision of the Technical Appeal Board.

It's in parallel proceedings brought by Germany, The Dusseldorf District Court has decided to hold a hearing on the matter in the near future. (Be compiled fromwww. juve-patent. com)

TRANSLATORS: Liu Peng　proofread: Wang Dan



　　disclaimer: This network reprint or compile the original articles are from the network, Does not represent the views of this website or confirm the authenticity of its content. If the source is mislabeled or the copyright of the article is involved, Please contact us, This website will be corrected in due course, delete, thank you.